Liver Cirrhosis Market Size in the 7MM was ~USD 3,100 Million in 2023, it is expected to grow by 2034, estimates DelveInsight

The liver cirrhosis market size was estimated at around USD 3,100 million in 2023 and is projected to expand at a notable compound annual growth rate (CAGR) over the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Liver Cirrhosis landscape.

In 2023, the liver cirrhosis market across the EU4 and the UK was valued at approximately USD 566 million. Germany accounted for the largest share among European countries, with a market size of nearly USD 152 million, while Spain represented the smallest market at around USD 77 million.

"In 2023, the United States recorded approximately 2,070 thousand diagnosed prevalent cases of liver cirrhosis, a figure expected to increase over the forecast period. The US accounted for the largest share of diagnosed cases among the 7 major markets (7MM), followed by the EU4, the UK, and Japan, which represented about 24% and 14% of total liver cirrhosis cases, respectively. During the same year, the EU4 and the UK together reported nearly 830 thousand diagnosed prevalent cases, with Germany contributing the highest number among European countries.

In Japan, the breakdown of diagnosed prevalent liver cirrhosis cases by etiology showed that MASH accounted for 13% of cases, followed by HCV at 45%, HBV at 15%, ALD at 26%, and PBC at 2%.

DelveInsight’s report “Liver Cirrhosis Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Liver Cirrhosis landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Liver Cirrhosis market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Liver Cirrhosis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Liver Cirrhosis Market Forecast

Some of the key facts of the Liver Cirrhosis Market Report:

• Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
• The Liver Cirrhosis epidemiology based on gender analyzed that males are more affected with Liver Cirrhosis than females
• The Liver Cirrhosis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.
• Furthermore, launching various multiple-stage Liver Cirrhosis pipeline products will significantly revolutionize the Liver Cirrhosis market dynamics.

Liver Cirrhosis Overview

Liver Cirrhosis is a chronic, progressive condition in which healthy liver tissue is replaced by scar tissue, impairing liver function. It results from long-term liver damage caused by factors such as chronic hepatitis (B or C), alcohol abuse, non-alcoholic fatty liver disease (NAFLD), or autoimmune disorders. Symptoms may include fatigue, jaundice, swelling in the abdomen or legs, and confusion. Advanced cirrhosis can lead to life-threatening complications such as liver failure, portal hypertension, and liver cancer.
 
Get a Free sample for the Liver Cirrhosis Market Report:

https://www.delveinsight.com/report-store/liver-cirrhosis-market

Key Trends in Liver Cirrhosis Therapeutics Market:

• Growth driven by innovative and targeted therapies: There’s increasing development of advanced pharmacological agents such as antifibrotic drugs, novel biologics, and agents targeting underlying mechanisms of cirrhosis rather than only symptom management, improving clinical outcomes.
• Integration of non-invasive diagnostics and digital health: Adoption of non-invasive imaging and biomarker tests for early detection, along with digital health tools (telemedicine, remote monitoring), is enhancing patient management, adherence, and personalized care.
• Shift toward regenerative and combination approaches: Research emphasis is growing on regenerative medicine, antifibrotic combinations, and precision therapies that aim to reverse liver damage and fibrosis rather than solely slow disease progression.
• Rising disease prevalence and healthcare investment: Increasing incidence of liver cirrhosis due to viral hepatitis, alcohol use, and metabolic-associated liver disease, paired with rising healthcare expenditure and specialized care units, is expanding the market demand globally. 
• Collaborations and tailored treatment strategies: Partnerships among pharma companies, research institutions, and healthcare systems are accelerating R&D, and there’s a trend toward personalized treatment regimens based on patient profiles and disease etiology.

Liver Cirrhosis Epidemiology

The Liver Cirrhosis epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Liver Cirrhosis Epidemiology Segmentation:

The Liver Cirrhosis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Liver Cirrhosis
• Prevalent Cases of Liver Cirrhosis by severity
• Gender-specific Prevalence of Liver Cirrhosis
• Diagnosed Cases of Episodic and Chronic Liver Cirrhosis

Download the report to understand which factors are driving Liver Cirrhosis epidemiology trends @ Liver Cirrhosis Epidemiology Forecast

Recent Development In The Liver Cirrhosis Treatment Landscape:

• In April 2025, Enrollment has been finalized for the Phase 3 NATiV3 clinical trial (NCT04849728), which is evaluating lanifibranor in individuals with metabolic dysfunction-associated steatohepatitis (MASH) and advanced liver fibrosis. According to the developer, Inventiva, if the results are favorable, the top-line data from this global study could support regulatory approval submissions for lanifibranor.
• In March 2025, According to two-year data from the Phase 3 MAESTRO-NAFLD-1 clinical trial (NCT04197479), long-term treatment with Rezdiffra (resmetirom) has been shown to reduce liver scarring in most individuals with compensated cirrhosis—irreversible scarring in a still-functioning liver caused by metabolic dysfunction-associated steatohepatitis (MASH). This finding was recently revealed by Madrigal Pharmaceuticals, the developer of the therapy.
• In March 2025, Akero Therapeutics’ experimental therapy efruxifermin has shown the ability to reverse compensated cirrhosis—permanent liver scarring with preserved function in adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease. These top-line results come from the Phase 2b SYMMETRY clinical trial (NCT05039450) and were described by the company as both “unprecedented” and statistically significant in a recent press release. The findings align with previous Phase 2b HARMONY trial (NCT04767529) data, which demonstrated that efruxifermin reduced liver fibrosis in patients with MASH who had not yet developed cirrhosis.
• In January 2025, Akero Therapeutics has announced preliminary topline results from week 96 of its Phase IIb SYMMETRY study evaluating efruxifermin (EFX) in adults with biopsy-confirmed compensated cirrhosis (F4), Child-Pugh Class A, caused by metabolic dysfunction-associated steatohepatitis (MASH). This placebo-controlled, multicenter, double-blind, dose-ranging, randomized trial focused on individuals with the condition.
• In December 2024, Galectin Therapeutics revealed findings from its global NAVIGATE clinical trial assessing belapectin in individuals with Metabolic Dysfunction-Associated Steatohepatitis (MASH) cirrhosis and portal hypertension.
• In October 2024, PharmaIN Corporation announced that it will present interim findings from its ongoing Phase I clinical trial of PHIN-214, its leading candidate for preventing and treating decompensated cirrhosis.

Liver Cirrhosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Liver Cirrhosis market or expected to get launched during the study period. The analysis covers Liver Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Liver Cirrhosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Liver Cirrhosis Therapies and Key Companies

• Resmetirom: Madrigal Pharmaceuticals Inc.
• Belapectin: Galectin Therapeutics
• Efruxifermin: AkeroTherapeutics
• LPCN 1148: Lipocine Inc
• IDN-6556: Conatus Pharma
• NRL972: Norgine
• Resmetirom: Madrigal Pharma
• GXHPC1: Gwo Xi Stem Cell Applied Tech
• GI262570: GlaxoSmithKline
• Rifaximin: Bausch Health
• BMS-986263: Bristol-Myers Squibb
• MNK6106: Mallinckrodt
• conivaptan: Cumberland Pharma
• LPCN 1148: Lipocine Inc.
• INT-747: Intercept Pharma
• Satavaptan: Sanofi
• oltipraz: HK inno.N Corporation
• Obeticholic Acid (OCA): Intercept Pharma
• IDN-6556: Conatus Pharmaceuticals Inc.
• Pregabalin: Pfizer

Discover more about therapies set to grab major Liver Cirrhosis market share @ Liver Cirrhosis Treatment Market

Liver Cirrhosis Market Drivers

• Rising prevalence of liver diseases leading to cirrhosis: Increased cases of NAFLD (non-alcoholic fatty liver disease), chronic hepatitis (B & C), alcoholic liver disease, obesity, and metabolic disorders are expanding the patient pool requiring cirrhosis management and therapeutics.
• Advancements in diagnostics and early detection: Improved non-invasive diagnostic tools like elastography, advanced imaging, and biomarker tests enable earlier and more accurate detection, enhancing treatment initiation and patient outcomes.
• Innovations in treatment options: Development of novel antifibrotic drugs, targeted therapies, immunomodulators, and regenerative medicine approaches is broadening therapeutic choices and improving clinical efficacy.
• Growing healthcare expenditure and awareness: Higher healthcare spending, increased public and private investment in liver disease care, along with awareness campaigns and screening programs, support market growth especially in emerging regions.
• Demographic shifts and lifestyle factors: Aging populations and lifestyle factors like unhealthy diets, alcohol consumption, and rising obesity contribute to chronic liver disease progression and sustained demand for cirrhosis treatments.

Liver Cirrhosis Market Barriers

• High cost of treatment and limited affordability: Advanced therapies, liver transplantation, hospitalization, and long-term care are expensive, limiting access especially in low- and middle-income countries.
• Limited access to healthcare infrastructure: Shortages of advanced diagnostic and treatment facilities in rural or underserved areas delay diagnosis and care, reducing overall market penetration.
• Complex disease pathophysiology and clinical challenges: The multifaceted nature of cirrhosis complicates the development of highly effective therapies, and clinical trials often face difficulties due to patient heterogeneity and comorbidities.
• Regulatory and approval hurdles: Lengthy and stringent regulatory processes for new drugs and therapies slow product launches, delaying patient access to innovative treatments.
• Diagnosis gaps and late presentation: Many patients remain undiagnosed until advanced stages of liver disease, which limits the effectiveness of available treatments and increases healthcare burden.

Scope of the Liver Cirrhosis Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Liver Cirrhosis Companies: Madrigal Pharmaceuticals Inc., Galectin Therapeutics, Akero Therapeutics, Lipocine Inc, Conatus Pharma, Norgine, Madrigal Pharma, Gwo Xi Stem Cell Applied Tech, GlaxoSmithKline, Bausch Health, Bristol-Myers Squibb, Mallinckrodt, Cumberland Pharma, Lipocine Inc., Intercept Pharma, Sanofi, HK inno.N Corporation, Pfizer, and others
• Key Liver Cirrhosis Therapies: Resmetirom, Belapectin, Efruxifermin, LPCN 1148, IDN-6556, NRL972, Resmetirom, GXHPC1, GI262570, Rifaximin, BMS-986263, MNK6106, conivaptan, LPCN 1148, INT-747, Satavaptan, oltipraz, Obeticholic Acid (OCA), IDN-6556, Pregabalin, and others
• Liver Cirrhosis Therapeutic Assessment: Liver Cirrhosis current marketed and Liver Cirrhosis emerging therapies
• Liver Cirrhosis Market Dynamics: Liver Cirrhosis market drivers and Liver Cirrhosis market barriers
• Liver Cirrhosis Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Liver Cirrhosis Unmet Needs, KOL’s views, Analyst’s views, Liver Cirrhosis Market Access and Reimbursement 

To know more about Liver Cirrhosis companies working in the treatment market, visit @ Liver Cirrhosis Clinical Trials and Therapeutic Assessment

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.